Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 183-193

  Simoens, Cindy ^a   Pauwels, Bea ^a   Vermorken, Jan B ^a   Pattyn, Greet G O ^a   Lambrechts, Hilde A J ^a   Breillout, Fabienne ^b   Lardon, Filip ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Cell cycle perturbation; Chemoradiation; Microtubule inhibitor; Radiosensitisation; Vinflunine

Indexed keywords

PROTEIN P53; VINCA ALKALOID; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL DISRUPTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; INCUBATION TIME; MICROTUBULE; PRIORITY JOURNAL; RADIATION; RADIOSENSITIZATION; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; GAMMA RAYS; HUMANS; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TUBULIN MODULATORS; VINBLASTINE;

EID: 43749085592     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0587-4     Document Type: Article

References (40)

1. Bennouna J, Breton JL, Tourani JM, Ottensmeier C, O'Brien M, Kosmidis P, Huat TE, Pinel MC, Colin C, Douillard JY (2006) Vinflunine-an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 94:1383-1388
2. Bennouna J, Campone M, Delord JP, Pinel MC (2005) Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs 14:1259-1267
3. Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M (2002) Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 7:159-166
4. Choy H, MacRae RM (2003) Chemoradiation: Biological principles and perspectives. In: Choy H (ed) Chemoradiation in Cancer Therapy. Humana Press, New Jersey, pp 3-22
5. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD (1993) Investigation of taxol as a potential radiation sensitizer. Cancer 71:3774-3778
6. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94:1395-1401
7. Edelstein MP, Wolfe LA 3rd, Duch DS (1996) Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23:41-47
8. Erenpreisa J, Cragg MS (2001) Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1:1-7
9. Etievant C, Kruczynski A, Barret JM, Tait AS, Kavallaris M, Hill BT (2001) Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol 48:62-70
10. Fahy J (2001) Modifications in the <> or Velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des 7:1181-1197
11. Fertil B, Dertinger H, Courdi A, Malaise EP (1984) Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99:73-84
12. Fukuoka K, Arioka H, Iwamoto Y, Fukumoto H, Kurokawa H, Ishida T, Tomonari A, Suzuki T, Usuda J, Kanzawa F, Kimura H, Saijo N, Nishio K (2002) Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells. Cancer Chemother Pharmacol 49:385-390
13. Fukuoka K, Arioka H, Iwamoto Y, Fukumoto H, Kurokawa H, Ishida T, Tomonari A, Suzuki T, Usuda J, Kanzawa F, Saijo N, Nishio K (2001) Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 34:451-460
14. Galmarini CM, Falette N, Tabone E, Levrat C, Britten R, Voorzanger Rousselot N, Roesch Gateau O, Vanier Viornery A, Puisieux A, Dumontet C, ELYPSE Study Group, UKCCSG and UK Canc Cytogenetics Group (2001) Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br J Cancer 85:902-908
15. Gorodetsky R, Levdansky L, Ringel I, Vexler A (1998) Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tu;or mammalian cells. Radiat Res 150:283-291
16. Hau PM, Siu WY, Womg N, Lai PBS, Poon RYC (2006) Polyploidization increases the sensitivity to DNA-damaging agents in mammalian cells. FEBS Lett 580:4727-4736
17. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A (1999) Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine in a panel of human tumour xenografts. Eur J Cancer 35:512-520
18. Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA (2000) Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. Cell Biol Int 24:621-633
19. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT (1998) Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55:635-648
20. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT (1998) Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41:437-447
21. Kruczynski A, Hill BT (2001) Vinflunine, the latest Vinca alkaloid in clinical development-a review of its preclinical anticancer properties. Crit Rev Oncol Hematol 40:159-173
22. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB (1994) In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446
23. Lobert S, Fahy J, Hill BT, Duflos A, Etievant C, Correia JJ (2000) Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. Biochemistry 39:12053-12062
24. McIntyre JA, Castaner J (2004) Vinflunine-Antimitotic-Vinca alkaloid. Drugs Future 29:574-580
25. Milas L, Milas MM, Mason KA (1999) Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 9:12-26
26. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA (2001) Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60:225-232
27. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L (2000) Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60:5045-5051
28. Okouneva T, Hill BT, Wilson L, Jordan MA (2003) The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2:427-436
29. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH (1997) Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208:151-158
30. Pauwels B, Korst AEC, de Pooter CMJ, Pattyn GGO, Lambrechts HAJ, Baay MFD, Lardon F, Vermorken JB (2003) Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 51:221-226
31. Plasswilm L, Cordes N, Sauer R (1998) Schedule-dependent interaction of paclitaxel (Taxol) and irradiation in vitro. Radiat Oncol Investig 6:10-17
32. Simoens C, Vermorken JB, Korst AE, Pauwels B, De Pooter CM, Pattyn GG, Lambrechts HA, Breillout F, Lardon F (2006) Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemother Pharmacol 58:210-218
33. Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450-474
34. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
35. Steel GG (2002) Cell survival as a determinant of tumour response. In: Steel GG (eds) Basic clinical radiobiology, 3rd edn. Hodder Arnold, London, pp 52-63
36. Steren A, Sevin BU, Perras J, Ramos R, Angioli R, Nguyen H, Koechli O, Averette HE (1993) Taxol as a radiation sensitizer: a flow cytometric study. Gynecol Oncol 50:89-93
37. Terasima R, Tolmach LJ (1963) X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140:490-492
38. Tishler RB, Geard CR, Hall EJ, Schiff PB (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495-3497
39. Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327
40. Zhang M, Boyer M, Rivory L, Hong A, Clarke S, Stevens G, Fife K (2004) Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 58:353-360